Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹8,646 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Aurobindo Pharma reported a strong quarter with PAT of INR 910 crore, supported by improving Pen G yields and a favorable government MIP policy on key antibiotics. The company is ramping Pen G production to over 10,000 metric tons annualized, with EBITDA breakeven already achieved. Europe continues double-digit growth, and the U.S. injectables business grew 17% despite the ongoing Eugia warning letter. Management guided for EBITDA margins in the 20-21% range for FY26 and expects meaningful contributions from Dayton and Raleigh facilities from FY27. Key risks include the timing of the Eugia warning letter resolution and potential delays in the Lannett acquisition.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects to achieve EBITDA margins on the higher side of 20-21% for FY2026, driven by Pen G ramp-up, injectable growth, and cost efficiencies.
- Based on current production levels, the company expects to produce more than 10,000 metric tons on an annualized basis over the next 12 months.
- The Dayton facility has transitioned to commercial phase and will begin contributing revenues significantly from FY2027 onwards.
- The acquisition is progressing well with FTC; expected to close in the first quarter of FY2027.
Risks flagged
- Despite procedural observations, the USFDA decision on the warning letter is pending; management is cautiously optimistic but cannot predict outcome.
- 6-APA prices have been below cost of manufacture internationally, causing losses; correction expected by April but timing uncertain.
- FTC approval process is ongoing; any delay or unexpected conditions could impact the timeline and synergies.
- EBITDA burn from ramping up facilities like Pen G, Dayton, Raleigh, and biosimilars may pressure near-term margins.
Key quotes
- We are cautiously optimistic about the future of this facility. But ultimately, USFDA has to take a decision in terms of the Warning Letter, so I cannot comment on what exactly they will do.
- The policy change will act as a very important and positive catalyst event for the company.
- We remain confident of achieving an EBITDA breakeven in Q4, and significantly, meaningfully contribute to the bottom line EBITDA in the next year.
Research modules